会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 에소메프라졸 함유 약학 조성물
    • 含有异喹诺酮的药物组合物
    • KR1020090033000A
    • 2009-04-01
    • KR1020080090692
    • 2008-09-16
    • 주식회사 씨티씨바이오
    • 이봉상권도우전홍렬곽성신문지윤이동진
    • A61K9/14A61K31/44A61K47/30
    • A61K31/4439A61K9/1611A61K9/2009
    • Provided is a pharmaceutical composition containing esomeprazole free base or alkaline salts thereof wherein the esomeprazole has improved stability for treating and preventing peptic ulcer and reflux oesophagitis as a proton pump inhibitor. A pharmaceutical composition containing esomeprazole includes solid-dispersion comprising esomeprazole free base or alkaline salts thereof, alkalizer, polyvinylpyrrolidone and vinylpyrrolidone-vinyl acetate copolymer. The alkalizer indicates MgO or Mg(OH)2. A method for producing the pharmaceutical composition containing esomeprazole consists of the following steps of: preparing a solution or suspension containing esomeprazole free base or alkaline salts thereof, magnesium oxide or magnesium hydroxide, polyvinylpyrrolidone, and vinylpyrrolidone-vinyl acetate copolymer; and drying the prepared solution or suspension.
    • 提供含有艾美拉唑游离碱或其碱式盐的药物组合物,其中艾美拉唑具有改善的稳定性,用于治疗和预防作为质子泵抑制剂的消化性溃疡和反流性食管炎。 含有艾美拉唑的药物组合物包括含有埃索美拉唑游离碱或其碱式盐,碱化剂,聚乙烯吡咯烷酮和乙烯基吡咯烷酮 - 乙酸乙烯酯共聚物的固体分散体。 碱化剂表示MgO或Mg(OH)2。 制备含有艾美拉唑的药物组合物的方法包括以下步骤:制备含有艾美拉唑游离碱或其碱式盐,氧化镁或氢氧化镁,聚乙烯吡咯烷酮和乙烯基吡咯烷酮 - 乙酸乙烯酯共聚物的溶液或悬浮液; 并干燥制备的溶液或悬浮液。
    • 5. 发明公开
    • 폴록사머 407 및 폴록사머 188을 포함하는 주사제
    • 包含POLOXAMER 407和POLOXAMER 188的耐热注射制剂
    • KR1020130079297A
    • 2013-07-10
    • KR1020120158334
    • 2012-12-31
    • 주식회사 씨티씨바이오
    • 이동진박현정곽성신이봉상전홍렬
    • A61K9/08A61K47/34A61K47/30
    • A61K47/34A61K9/0019
    • PURPOSE: An injection formulation containing poloxamer 407 and poloxamer 188 is provided to extend a cellular interval maintaining time and to enable easy injection and manipulation, thereby being used in various fields such as tissue cushion or tissue detachment. CONSTITUTION: An injection formulation is injected to a tissue for enlarging the interval between cells. The injection formulation contains poloxamer 407 and poloxamer 188. The injection formulation contains less than 15 wt% of a mixture of poloxamer 407 and poloxamer 188. The injection formulation contains less than 10 wt% of poloxamer 407. A method for enlarging the interval between cells comprises the step of injecting a injection solution into an isolated tissue. [Reference numerals] (AA) Poloxamer total weight 20%; (BB) Viscosity (p); (CC) Temperature (°C)
    • 目的:提供含有泊洛沙姆407和泊洛沙姆188的注射制剂,以延长细胞间隔保持时间,并且能够容易地进行注射和操作,从而用于各种领域,例如组织垫或组织分离。 构成:将注射制剂注射到组织中以扩大细胞间的间隔。 注射制剂含有泊洛沙姆407和泊洛沙姆188.注射制剂含有少于15重量%的泊洛沙姆407和泊洛沙姆188的混合物。注射制剂含有少于10重量%的泊洛沙姆407。一种用于扩大细胞间隔的方法 包括将注射溶液注射到分离的组织中的步骤。 (AA)泊洛沙姆总重量20%; (BB)粘度(p); (CC)温度(℃)